Press Releases

Recent & Archived News

March 19, 2019

Bayer Statement on Jury's Decision in Phase 1 of California Glyphosate Trial

Bayer released the following statement in reaction to a phase one verdict in favor of the plaintiff in the case of Hardeman v Monsanto, a trial conducted in the federal glyphosate multi-district...

Learn more
March 17, 2019

Bayer statement on new 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease

No one should start, stop or modify an aspirin regimen without first speaking with their healthcare provider. With the recent changes in the cardiovascular guidelines by the American College of...

Learn more
March 14, 2019

Bayer's Phase III Clinical Trial Of Nifurtimox In Pediatric Patients With Chagas Disease Meets Primary Endpoint

Bayer presented results today from the CHICO part (CHagas disease In Children treated with NifurtimOx) of the phase III clinical study of investigational nifurtimox in pediatric patients with...

Learn more
March 13, 2019

Bayer Earns Top Honors at National 4-H Legacy Awards

Bayer's longstanding commitment to American youth was recognized last night when the company received the National 4-H Council's 2019 Corporate Leadership Award during ceremonies in Washington,...

Learn more
March 07, 2019

Delaro® fungicide raises the bar on yields in first season on the market

The results are in, and in its debut season, fields treated with Delaro® fungicide from Bayer yielded more than the untreated checks. Across the nation, Delaro on average increased corn yield by...

Learn more
March 05, 2019

The Climate Corporation and NAU Country Insurance Company Partner to Enable Seamless Crop Insurance Reporting for U.S. Farmers

The Climate Corporation (Climate), a subsidiary of Bayer, announced today a platform agreement between the company's industry-leading Climate FieldView™ digital agriculture platform and NAU...

Learn more
February 27, 2019

Bayer completes rolling submission of New Drug Application to U.S. Food and Drug Administration for investigational drug darolutamide for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC)

Bayer today announced the completion of the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the investigational drug darolutamide. The...

Learn more
February 26, 2019

Open Dialogue and Transparency Drive Progress in Modern Agriculture and Consumer Acceptance

People around the world seem to be more divided on important food and agricultural topics than ever before. The use of on-farm technologies, breakthroughs like CRISPR, and how to address...

Learn more
February 21, 2019

'Wall Smashing' Ceremony Initiates Construction Of Bayer Funded Geospatial Innovation And Resource Center at T-REX Business Incubator

Sledgehammers breaking through a mock wall signaled the construction start of the new 'Geosaurus, Powered by Bayer' Innovation Resource Center at T-REX, a St. Louis based advanced technology...

Learn more
February 15, 2019

Bayer to obtain full rights to global development and commercialization of oncology compounds Vitrakvi® (larotrectinib) and BAY 2731954 (LOXO-195)

Bayer has exercised its option, under a change-in-control clause in the collaboration agreement with Loxo Oncology, to obtain the exclusive licensing rights for the global development and...

Learn more


Want even more Bayer news?

Check out our Social Media & Blogs.